This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove Drug Development Remove Pharma Conference Related Topics
Biosimilars Clinical Pharmacology Packaging Licensing Regulations Therapies Pharmaceuticals Trials Treatment Disease More Related Topics >
article thumbnail

Analysis Life Sciences Thank You What We Expect the FDA to do in May and June 2024

Agency IQ

MAY 3, 2024

Title Type Comments Close Key Information and Facilitating Understanding in Informed Consent Guidance for Sponsors, Investigators, and Institutional Review Boards Draft Guidance April 30 Early Alzheimer’s Disease: Developing Drugs for Treatment Draft Guidance May 13 Select Updates for the Premarket Cybersecurity Guidance: Section 524B of the (..)

FDA 40
FDA Science Regulations Clinical Trials 40
article thumbnail

Analysis Life Sciences Thank You What We Expect the FDA to do in August and September 2024

Agency IQ

AUGUST 2, 2024

Start Date End Date Event Event Type Center 07/30/2024 07/30/2024 Environmental Monitoring in Compounding Virtual CDER 08/02/2024 08/02/2024 UPDATED PUBLIC PARTICIPATION INFORMATION: August 2, 2024: Meeting of the Genetic Metabolic Diseases Advisory Committee Meeting Announcement Advisory Committee Meeting CDER 08/07/2024 08/07/2024 Medical Device (..)

FDA 40
FDA Science Regulations Biosimilars 40
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 15,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024